Tao Peng
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 32
- Cancer Research top 2%
- Cancer-related molecular mechanisms research 17
- Cancer, Lipids, and Metabolism 16
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 24
- Epidemiology top 5%
- Liver Disease Diagnosis and Treatment 24
- Hepatitis B Virus Studies 17
-
- Ferroptosis and cancer prognosis 25
-
- RNA modifications and cancer 21
- Co-authors
- Zhengwei FuXinping YeYuanxiang JinChuangye HanGuangzhi ZhuXiwen LiaoZhenzhen LiuZhengtao Liu
- Journals
- Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (4 papers)PLoS ONE (3 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Tao Peng
167 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 148
- Hepatology 624
- Cancer Research 848
- Health, Toxicology and Mutagenesis 512
- Oncology 529
- Epidemiology 649
Countries citing papers authored by Tao Peng
This map shows the geographic impact of Tao Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tao Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tao Peng more than expected).
Fields of papers citing papers by Tao Peng
This network shows the impact of papers produced by Tao Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tao Peng. The network helps show where Tao Peng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tao Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 11 | |
| 2 | 2025 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 14 | |
| 5 | 2024 | 4 | |
| 6 | 2023 | 7 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 15 | |
| 9 | 2023 | 6 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 8 | |
| 12 | 2023 | 6 | |
| 13 | Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy | 2022 | 7 |
| 14 | High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma | 2022 | 8 |
| 15 | 2020 | 7 | |
| 16 | 2019 | 10 | |
| 17 | 2015 | 9 | |
| 18 | 2013 | 35 | |
| 19 | 2012 | 15 | |
| 20 | Cloning of the Promoter Regions of Golgi Membrane Glycoprotein GP73 | 2008 | 1 |
About Tao Peng
Tao Peng is a scholar working on Hepatology, Cancer Research and Oncology, having authored 176 papers that have together received 3.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (32 papers), Ferroptosis and cancer prognosis (25 papers), Pancreatic and Hepatic Oncology Research (24 papers), Liver Disease Diagnosis and Treatment (24 papers), RNA modifications and cancer (21 papers), Hepatitis B Virus Studies (17 papers), Cancer-related molecular mechanisms research (17 papers) and Cancer, Lipids, and Metabolism (16 papers). The work is most often cited by research in Hepatology (624 citations), Cancer Research (848 citations) and Health, Toxicology and Mutagenesis (512 citations). Tao Peng has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Zhengwei Fu, Xinping Ye, Yuanxiang Jin, Chuangye Han, Guangzhi Zhu, Xiwen Liao, Zhenzhen Liu, Zhengtao Liu, Chengkun Yang and Shuping Que. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.